AUA 2025 BOND-003 Cohort C, Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ.
AUA 2025, Trends in Urology Residency Applications, Results from The American Urological Association Medical Student Survey from 2022 to 2024.
AUA 2025, pelvic lymph node dissection (PLND), Radical Prostatectomy, Trends In Use of Pelvic Lymph Node Dissection During Radical Prostatectomy.
AUA 2025 SOPHIA study, UroActiveTM implantable electronic artificial urinary sphincter (AUS), male stress urinary incontinence, occlusive urethral cuff, bulbar urethra.
AUA 2025 phase 3 CREST study, Sasanlimab in combination with BCG, transurethral resection of bladder tumor (TURBT), high-risk non-muscle-invasive bladder cancer.
AUA 2025 Bladder EpiCheck-triggered photodynamic diagnosis biopsies, white light cystoscopy (WLC), PhotoDynamic Diagnosis, Bladder EpiCheck.
AUA 2025 artificial intelligence-powered predictive biomarker, intravesical BCG versus gemcitabine + docetaxel in high-grade, non-muscle invasive bladder cancer (NMIBC) patients, EA-8212 (BRIDGE), computational histology artificial…
AUA 2025 disitamab vedotin combined with BCG for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC), HER2 expression.
AUA 2025 results of ENVISION, UGN-102, non-muscle invasive bladder cancer (NMIBC), ENVISION trial, urinary retention, urethral stenosis.
AUA 2025 cost-effectiveness analysis of 89Zr-girentuximab PET-CT (TLX250) to guide management of small renal masses,
AUA 2025 prostate cancer clinical trials in the VA, veterans with prostate cancer, VA healthcare system.
